Insider Garo Armen Files SC 13D for MiNK Therapeutics

TL;DR

**Garo Armen just filed a 13D on MiNK Therapeutics, signaling significant insider ownership.**

AI Summary

Garo H. Armen filed an SC 13D on February 14, 2024, concerning MiNK Therapeutics, Inc. common stock, which has a par value of $0.00001 per share and CUSIP 603693102. The event requiring this filing occurred on January 16, 2024. MiNK Therapeutics, Inc. was formerly known as AgenTus Therapeutics, Inc. until January 12, 2021.

Why It Matters

This filing indicates that Garo H. Armen, a significant individual associated with MiNK Therapeutics, has a beneficial ownership stake requiring disclosure, providing transparency to investors about major shareholders.

Risk Assessment

Risk Level: low — This is a standard disclosure filing by an insider, not indicating any immediate negative or highly volatile event.

Key Numbers

• $0.00001 — Par Value per Share (Common Stock of MiNK Therapeutics, Inc.)
• 603693102 — CUSIP Number (MiNK Therapeutics, Inc. Common Stock)

Key Players & Entities

• Garo H. Armen (person) — filer of SC 13D
• MiNK Therapeutics, Inc. (company) — subject company of SC 13D
• AgenTus Therapeutics, Inc. (company) — former name of MiNK Therapeutics, Inc.
• 03 Life Sciences (company) — organization name associated with subject company data
• $0.00001 (dollar_amount) — par value per share of Common Stock
• January 16, 2024 (date) — date of event requiring filing
• February 14, 2024 (date) — filing date

FAQ

Key Financial Figures

• $0.00001 — Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class o
• $94,850 — 2023, the Dr. Armen used approximately $94,850 of personal funds to purchase 100,000 s
• $0.01 — lders of Agenus common stock, par value $0.01 per share as of the close of business o

Filing Documents

• d763069dsc13d.htm (SC 13D) — 62KB
• d763069dex991.htm (EX-99.1) — 4KB
• 0001193125-24-036660.txt ( ) — 68KB

From the Filing

SC 13D 1 d763069dsc13d.htm SC 13D SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* MiNK Therapeutics, Inc. (Name of Issuer) Common Stock, $0.00001 par value per share (Title of Class of Securities) 603693102 (CUSIP Number) Garo H. Armen, Ph.D. c/o MiNK Therapeutics, Inc. 149 Fifth Avenue Suite 500 New York, NY 10010 Telephone: (781) 674-4400 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) January 16, 2024 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 603693102 1. Name of Reporting Persons Garo H. Armen 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) PF, OO 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization United States of America Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 3,514,320* 8. Shared Voting Power 0 9. Sole Dispositive Power 3,514,320 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 3,514,320 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 9.68%** 14. Type of Reporting Person (See Instructions) IN * Includes (i) 728,010 shares of common stock held directly by the Reporting Person, (ii) 657,315 are held by the Garo H. Armen Grantor Retained Annuity Trust Agreement 2023 #1 (the 2023 GRAT), (iii) 342,685 are held by the Garo H. Armen Grantor Retained Annuity Trust Agreement 2022 #1 (the 2022 GRAT and, together with the 2023 GRAT, the GRATs) and (iv) 1,786,310 shares of common stock issuable to the Reporting Person upon exercise of stock options that are exercisable as of the date hereof or will become exercisable within 60 days of such date. The Reporting Person is a director and executive officer of Agenus Inc. (Agenus). He may influence voting and disposition of the shares of the Issuers common stock held by Agenus. ** Based on an aggregate of 34,519,540 shares of the Issuers common stock reported to be outstanding as of November 3, 2023, as disclosed in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. 1. Name of Reporting Persons The Garo H. Armen Grantor Retained Annuity Trust Agreement 2023 #1 2. Check the Appropriate Box if a Member of a Group (See Instructions) (a)(b) 3. SEC USE ONLY 4. Source of Funds (See Instructions) OO 5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization Missouri Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power 657,315 8. Shared Voting Power 0 9. Sole Dispositive Power 657,315 10. Shared Dispositive Power 0 11. Aggregate Amount Beneficially Owned by Each Reporting Person 657,315 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) 13. Percent of Class Represented by Amount in Row (11) 1.90%* 14. Type of Reporting Person (See Instructions) OO * Based on an aggregate of 34,519,540 shares of the Issuers common stock reported to be outstanding as of November 3, 2023, as disclosed in the Issuers Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. 1. Name of Reporting Persons The Garo H. Armen Grantor Retained Annuity Trust Agreement 2022 #1 2. Check the Appropriate Box if a Member of a Group (See Instructions)

View Full Filing

View this SC 13D filing on SEC EDGAR